Actinium Pharmaceuticals, Inc. ATNM
1.20
0.01
0.84%
as of 25 Sep
- Market cap
- $37.4M
- P/E
- 3.3×
Follow ATNM
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
P/S ratio |
— | — | — | — | — | 108.06 | 234.86 | 137.41 | — | 235.70 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 29.22 | 0.00 | — | 0.00 |
P/Operating CF |
— | — | — | — | — | (24.47) | (31.10) | (18.90) | — | (8.02) |
P/B ratio |
— | — | — | — | — | 1.68 | 3.64 | 3.89 | — | 5.42 |
Price to Tangible BV |
— | — | — | — | — | 1.68 | 3.64 | 3.89 | — | 5.42 |
EV/Sales |
— | — | — | — | — | 39.91 | 131.24 | 63.49 | — | (28.04) |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.14 |
EV/Operating CF |
— | — | — | — | — | (2.19) | 15.64 | (1.38) | — | 0.21 |
EV/FCF |
— | — | — | — | — | (2.17) | 16.33 | (1.38) | — | 0.20 |
Quick Ratio |
4.55 | 3.73 | 2.26 | 1.74 | 13.34 | 11.44 | 10.28 | 9.03 | 8.95 | 6.02 |
Current Ratio |
4.95 | 3.82 | 2.36 | 1.89 | 13.62 | 11.66 | 10.44 | 9.21 | 9.14 | 6.20 |
Net Debt/EBITDA |
0.77 | 0.65 | 0.58 | 0.42 | 2.90 | 3.20 | 3.21 | 1.50 | 1.76 | 1.35 |
Debt/Assets |
0.00% | 0.00% | 0.09% | 1.29% | 0.10% | 0.00% | 1.82% | 0.02% | 0.01% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.81 | 0.87 | 0.98 | 0.97 | 0.84 | (0.26) | 0.97 | 0.86 | 0.73 |
Capex/Depreciation |
(0.77) | (0.44) | (1.90) | (0.15) | (0.57) | (0.25) | (0.52) | (0.19) | (0.01) | (0.13) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (121.66%) | (167.94%) | (210.41%) | (302.99%) | (66.35%) | (36.74%) | (47.16%) | (94.92%) | (110.63%) | (166.96%) | |
| (99.04%) | (130.19%) | (142.38%) | (164.92%) | (56.92%) | (33.76%) | (33.94%) | (49.91%) | (48.30%) | (52.67%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(135.43%) | (201.06%) | (282.09%) | (450.92%) | (36.74%) | (33.82%) | (32.72%) | (69.42%) | (57.32%) | (81.25%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,576.14% | 2,246.12% | 47,740.74% | 0.00% | 23,471.11% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 706.03% | 1,164.95% | 16,458.02% | 0.00% | 16,903.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 148.08% | 271.36% | 4,743.21% | 0.00% | 10,211.11% |
Graham Net Nets |
— | — | — | — | — | 0.59 | 0.26 | 0.23 | — | 0.13 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Earnings Yield |
— | — | — | — | — | (20.11%) | (13.57%) | (34.40%) | — | (79.41%) |
Free Cash Flow Yield |
— | — | — | — | — | (16.99%) | 3.42% | (33.55%) | — | (58.18%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(12.88) | (9.70) | (5.83) | (4.31) | (1.78) | (1.01) | 0.36 | (1.78) | (1.10) | (0.79) |
Capex per Share |
(0.04) | (0.01) | (0.03) | (0.01) | (0.02) | (0.01) | (0.02) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(12.92) | (9.71) | (5.85) | (4.33) | (1.80) | (1.02) | 0.34 | (1.78) | (1.10) | (0.79) |
Cash per Share |
12.74 | 7.83 | 3.88 | 1.87 | 5.24 | 3.81 | 4.53 | 2.88 | 2.42 | 1.54 |
Shareholders Equity per Share |
11.16 | 6.15 | 2.50 | 1.13 | 5.05 | 3.58 | 2.75 | 1.37 | 1.09 | 0.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.16 | 6.15 | 2.50 | 1.13 | 5.05 | 3.58 | 2.75 | 1.37 | 1.09 | 0.25 |
Free Cash Flow |
(20.85) | (21.58) | (20.67) | (21.53) | (21.87) | (21.00) | 8.28 | (47.49) | (33.08) | (24.68) |
Working Capital |
17.87 | 13.17 | 8.27 | 4.74 | 60.16 | 72.91 | 100.31 | 69.77 | 66.36 | 41.41 |
Capital Expenditures |
(0.06) | (0.02) | (0.10) | (0.06) | (0.25) | (0.13) | (0.37) | (0.15) | (0.01) | (0.10) |
Net Current Asset Value |
17.87 | 13.17 | 8.25 | 4.06 | 59.85 | 72.91 | 63.23 | 33.20 | 30.37 | 5.44 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.14 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.36 | 1.89 | 0.00 | 1.16 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,165.56%) | (3,205.53%) | (60,269.14%) | 0.00% | (37,652.22%) |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.88 | 0.97 | 0.43 | 3.72 | 1.43 | 1.54 | 1.16 | 1.44 | 2.23 | 2.78 |
Cash ROIC |
(54.14%) | (69.55%) | (91.79%) | (142.91%) | (17.54%) | (13.97%) | 4.52% | (42.35%) | (31.64%) | (44.55%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
2.86 | 4.44 | 5.23 | 5.21 | 4.47 | 4.94 | 7.83 | 9.04 | 7.76 | 7.41 |
Average Assets |
24.56 | 20.43 | 16.61 | 13.28 | 39.03 | 73.39 | 97.29 | 97.82 | 79.17 | 64.34 |
Average Common Equity |
19.99 | 15.84 | 11.24 | 7.23 | 33.48 | 67.43 | 70.01 | 51.43 | 34.57 | 20.30 |
Columns are period end dates